TRANSCENDING MECHANICAL SOLUTIONS FOR DIALYSIS ACCESS


GORE[®] PROPATEN[®] Vascular Graft



Together, improving life

Clinical experience

Significant 20% improvement in clot-free survival as compared to the control group. — Ingemar Davidson, M.D.¹ UT Southwestern Dallas, Texas



Study results

	Standard ePTFE n = 29	GORE® PROPATEN® Vascular Graft n = 24
n	29	24
Thrombosis n	11 (38%)	5 (21%)
Interventions n	19	8
Interventions per patient year	2.6	0.8


Addressing vascular graft failure modes

Thrombosis

The bioactive luminal surface of a 3 mm diameter GORE® PROPATEN® Vascular Graft remains free of thrombus, while the non-bioactive surface of a control graft (3 mm diameter) is covered with thrombus. Grafts were explanted after two hours in a challenging carotid shunt canine model. — Begovac, et al.³



GORE[®] PROPATEN[®] Vascular Graft



Control ePTFE graft

Intimal hyperplasia

Neointimal hyperplasia at the distal anastomoses of an aortoiliac bypass graft model in baboons. Statistically significant reduction in neointimal hyperplasia at the distal anastomosis was observed for the GORE® PROPATEN® Vascular Graft as compared to untreated control ePTFE. — Lin, et al.⁴




GORE[®] PROPATEN[®] Vascular Graft



Control ePTFE graft

A: Distal anastomosis of untreated control ePTFE graft B: Distal anastomosis of the GORE® PROPATEN® Vascular Graft. L: Lumen; N: Neointima; G: ePTFE Graft. Collagens are blue, elastin is black, others are red. (Verhoeff-Masson stain; original magnification X40) Images reproduced with permission from Elsevier.

Proprietary end-point covalent bonding



Selected literature

- 1 Davidson I, Hackerman C, Kapadia A, Minhajuddib A. Heparin bonded hemodialysis e-PTFE grafts result in 20% clot free survival benefit. *Journal of Vascular Access* 2009;10(3):153-156.
- 2 Shemesh D, Goldin I, Zaghal I, Berelowitz D, Verstandig A, Olsha O. Heparin-bonded graft (PROPATEN[®]) versus standard graft in prosthetic arteriovenous access. Abstract presented at the 6th International Congress of the Vascular Access Society (VAS); April 20-22, 2009; Rome, Italy. *Journal of Vascular Access* 2009;10(2):100-101.
- 3 Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX[®] Vascular Graft performance by Carmeda[®] bioactive surface heparin immobilization. *European Journal of Vascular & Endovascular Surgery* 2003;25(5):432-437.
- 4 Lin PH, Chen C, Bush RL, Yao Q, Lumsden AB, Hanson SR. Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model. *Journal of Vascular Surgery* 2004;39(6):1322-1328.

Consult Instructions for Use

eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. $R_{x_{only}}$

Products listed may not be available in all markets.

GORE, *Together, improving life,* PROPATEN and designs are trademarks of W. L. Gore & Associates. © 2023 W. L. Gore & Associates GmbH 23952205-EN MARCH 2023

W. L. Gore & Associates, Inc. goremedical.com

 Asia Pacific +65
 6733
 2882
 Australia/New Zealand
 1800
 680
 424
 Europe
 00800
 6334
 4673

 United States
 Flagstaff, AZ
 86004
 800
 437
 8181
 928
 779
 2771

